Cargando…
Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. The WHO recently re...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249579/ https://www.ncbi.nlm.nih.gov/pubmed/25267661 http://dx.doi.org/10.1128/AAC.03704-14 |
_version_ | 1782346862595932160 |
---|---|
author | Hanboonkunupakarn, Borimas Ashley, Elizabeth A. Jittamala, Podjanee Tarning, Joel Pukrittayakamee, Sasithon Hanpithakpong, Warunee Chotsiri, Palang Wattanakul, Thanaporn Panapipat, Salwaluk Lee, Sue J. Day, Nicholas P. J. White, Nicholas J. |
author_facet | Hanboonkunupakarn, Borimas Ashley, Elizabeth A. Jittamala, Podjanee Tarning, Joel Pukrittayakamee, Sasithon Hanpithakpong, Warunee Chotsiri, Palang Wattanakul, Thanaporn Panapipat, Salwaluk Lee, Sue J. Day, Nicholas P. J. White, Nicholas J. |
author_sort | Hanboonkunupakarn, Borimas |
collection | PubMed |
description | Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. The WHO recently reinforced its recommendations to add a single dose of primaquine to ACTs to reduce P. falciparum transmission in low-transmission settings. The pharmacokinetics of primaquine and dihydroartemisinin-piperaquine were evaluated in 16 healthy Thai adult volunteers in a randomized crossover study. Volunteers were randomized to two groups of three sequential hospital admissions to receive 30 mg (base) primaquine, 3 tablets of dihydroartemisinin-piperaquine (120/960 mg), and the drugs together at the same doses. Blood sampling was performed over 3 days following primaquine and 36 days following dihydroartemisinin-piperaquine dosing. Pharmacokinetic assessment was done with a noncompartmental approach. The drugs were well tolerated. There were no statistically significant differences in dihydroartemisinin and piperaquine pharmacokinetics with or without primaquine. Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (C(max)), area under the concentration-time curve from 0 h to the end of the study (AUC(0–last)), and area under the concentration-time curve from 0 h to infinity (AUC(0–∞)) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively. This interaction is similar to that described recently with chloroquine and may result in an enhanced radical curative effect. (This study has been registered at ClinicalTrials.gov under registration no. NCT01525511.) |
format | Online Article Text |
id | pubmed-4249579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-42495792014-12-31 Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects Hanboonkunupakarn, Borimas Ashley, Elizabeth A. Jittamala, Podjanee Tarning, Joel Pukrittayakamee, Sasithon Hanpithakpong, Warunee Chotsiri, Palang Wattanakul, Thanaporn Panapipat, Salwaluk Lee, Sue J. Day, Nicholas P. J. White, Nicholas J. Antimicrob Agents Chemother Clinical Therapeutics Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. The WHO recently reinforced its recommendations to add a single dose of primaquine to ACTs to reduce P. falciparum transmission in low-transmission settings. The pharmacokinetics of primaquine and dihydroartemisinin-piperaquine were evaluated in 16 healthy Thai adult volunteers in a randomized crossover study. Volunteers were randomized to two groups of three sequential hospital admissions to receive 30 mg (base) primaquine, 3 tablets of dihydroartemisinin-piperaquine (120/960 mg), and the drugs together at the same doses. Blood sampling was performed over 3 days following primaquine and 36 days following dihydroartemisinin-piperaquine dosing. Pharmacokinetic assessment was done with a noncompartmental approach. The drugs were well tolerated. There were no statistically significant differences in dihydroartemisinin and piperaquine pharmacokinetics with or without primaquine. Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (C(max)), area under the concentration-time curve from 0 h to the end of the study (AUC(0–last)), and area under the concentration-time curve from 0 h to infinity (AUC(0–∞)) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively. This interaction is similar to that described recently with chloroquine and may result in an enhanced radical curative effect. (This study has been registered at ClinicalTrials.gov under registration no. NCT01525511.) American Society for Microbiology 2014-12 /pmc/articles/PMC4249579/ /pubmed/25267661 http://dx.doi.org/10.1128/AAC.03704-14 Text en Copyright © 2014 Hanboonkunupakarn et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license (http://creativecommons.org/licenses/by/3.0/) . |
spellingShingle | Clinical Therapeutics Hanboonkunupakarn, Borimas Ashley, Elizabeth A. Jittamala, Podjanee Tarning, Joel Pukrittayakamee, Sasithon Hanpithakpong, Warunee Chotsiri, Palang Wattanakul, Thanaporn Panapipat, Salwaluk Lee, Sue J. Day, Nicholas P. J. White, Nicholas J. Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects |
title | Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects |
title_full | Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects |
title_fullStr | Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects |
title_full_unstemmed | Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects |
title_short | Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects |
title_sort | open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects |
topic | Clinical Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249579/ https://www.ncbi.nlm.nih.gov/pubmed/25267661 http://dx.doi.org/10.1128/AAC.03704-14 |
work_keys_str_mv | AT hanboonkunupakarnborimas openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT ashleyelizabetha openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT jittamalapodjanee openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT tarningjoel openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT pukrittayakameesasithon openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT hanpithakpongwarunee openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT chotsiripalang openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT wattanakulthanaporn openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT panapipatsalwaluk openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT leesuej openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT daynicholaspj openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects AT whitenicholasj openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects |